- AZ304
-
- $35.00
-
2026-07-27
- CAS:942507-42-8
- Purity: 99.83%
- Supply Ability: 10g
|
| Product Name: | AZ304 | | Synonyms: | AZ304;AZ-304;AZ 304;AZ304;Benzamide, 3-(1-cyano-1-methylethyl)-N-[3-[(7-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-;3-(2-Cyanopropan-2-yl)-N-(3-((7-methoxyquinazolin-4-yl)amino)-4-methylphenyl)benzamide;3-(2-Cyano-2-propanyl)-N-{3-[(7-methoxy-4-quinazolinyl)amino]-4-methylphenyl}benzamide;inhibit,AZ 304,Raf kinases,Autophagy,AZ304,Inhibitor,AZ-304,Raf;AZ304, 10 mM in DMSO;AZ304 ，S8755 | | CAS: | 942507-42-8 | | MF: | C27H25N5O2 | | MW: | 451.52 | | EINECS: | | | Product Categories: | API | | Mol File: | 942507-42-8.mol |  |
| | AZ304 Chemical Properties |
| Boiling point | 582.6±50.0 °C(Predicted) | | density | 1.270±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 12.87±0.70(Predicted) | | color | White to off-white |
| | AZ304 Usage And Synthesis |
| Uses | AZ304 is potent dual BRAF inhibitor. Is a combination of MEK and B-raf inhibitors for treatment of cancer. | | Biological Activity | AZ304 is a synthetic inhibitor targeting wild-type and V600E mutant BRAF with IC50 of 79 nM and 38 nM, respectively. It also inhibits CRAF, p38 and CSF1R with IC50 below 100 nM. | | in vitro | AZ304 inhibited wild-type BRAF and CRAF, BRAF in vitro. | | in vivo | In both RKO and Caco-2 tumor models, administration of AZ304 alone or in combination with Cetuximab resulted in antitumor activity without apparent toxic effects (regardless of BRAF mutation). | | target | | Target | Value | p38
(Cell-free assay) | 6 nM | CSF1R
(Cell-free assay) | 35 nM | < td style="border-bottom: 1px dotted #ccc;padding: 5px;"> BRAF(V600E)
(Cell-free assay) 38 nM | CRAF
(Cell-free assay ) | 68 nM | WT BRAF
(Cell-free assay) | 79 nM | < /tr>
| | IC 50 | BRafV600E: 38 nM (IC50); BRAFWT: 79 nM (IC50); CRAF: 68 nM (IC50); p38: 6 nM (IC50); CSF1R: 35 nM (IC50); MAP3K7: 6400 nM (IC50); CSK: 7050 nM (IC50) |
| | AZ304 Preparation Products And Raw materials |
|